Monrovia, California-based Xencor, which is developing antibodies to treat such things as Hodgkin lymphoma and inflammatory disease, said this morning that it has inked a technology license and evaluation agreement with Pfizer. According to the firm, the deal calls for it to "optimize the performance" of therapeutic monoclocal antibodies at Pfizer. Financial terms of the licensing deal were not disclosed. Xencor said it will receive an upfront payment for Pfizer to access its technology, and that it is elegible for additional consideration as Pfizer commercializes products incorporating Xencor's technology.
Top NewsMonday, March 2, 2009
Xencor In License Deal With Pfizer